Abbvie Deutschland Gmbh and Co Kg

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Gmbh & Co Kg

Barrier Therapeutics, Inc.

Matthias Degenhardt

Gunther Berndl

Joerg Rosenberg

Joerg Breitenbach

Thomas Kessler

Jörg Breitenbach

Jörg Rosenberg

Christoph Schmidt

Harald Krull

Markus Maegerlein

Gerrit Dispersyn

Geoff G Zhang

Yuchuan Gong

Markus Mägerlein

Markus Mäegerlein

Katja Fastnacht

A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (), each of the shafts () carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (R; A), (ii) at least one reverse-flight section (D), and (iii) a discharging section (E), wherein the processing elements defining the reverse-flight section (R; D) comprise at least one reverse-flight element () which is based on a screw-type element having a conveying direction being opposite to the general conveying direction of the extruder.

Process for producing a solid dispersion of an active ingredient

A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (), each of the shafts () carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (A), (ii) at least one mixing section (B), and (iii) a discharging section (E), wherein the processing element(s) defining the mixing section (B) comprise(s) a mixing element () that is derived from a screw type element (FIG.).

This invention relates to novel crystalline lopinavir/surfactant adducts, methods for their preparation, therapeutic uses of those crystalline lopinavir/surfactant adducts, and pharmaceutical compositions containing them or made from them.

Crystalline lopinavir/surfactant adducts

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35&#x3e;&#x394;H(1) (wherein &#x394;Hrepresents the endotherm (J/g) accompanying a transition at about 240&#xb0; C.). The solid dispersion product shows an improved bioavailability.

Itraconazole compositions with improved bioavailability

A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35&#x3e;&#x394;H(1) (wherein AHrepresents the endotherm (J/g) accompanying a transition at about 240&#xb0; C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.

Dosage forms with improved bioavailability

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35&#x3e;&#x394;H(1) (wherein &#x394;Hrepresents the endotherm (J/g) accompanying a transition at about 240&#xb0; C). The solid dispersion product shows an improved bioavailability.

Growing community of inventors

Ludwigshafen, Germany

Matthias Degenhardt